Global Intravascular Lithotripsy Market Report 2025–2032

 The global intravascular lithotripsy (IVL) market is entering a period of rapid expansion, propelled by the rising prevalence of calcified arterial conditions, increasing adoption of minimally invasive cardiovascular treatments, and the accelerated pace of technological innovation. Market estimates suggest that the global IVL market will grow from US$1,036.2 million in 2025 to US$2,837.7 million by 2032, registering a strong compound annual growth rate (CAGR) of 15.5% during the forecast period.

Market Overview

Intravascular lithotripsy is a relatively new but transformative technology in the treatment of cardiovascular diseases, particularly those complicated by calcified arterial blockages. The therapy involves the use of shockwaves delivered inside blood vessels to break up calcified plaques, thereby improving vessel compliance and allowing optimal stent placement. Unlike traditional methods such as atherectomy, which involves physically cutting or shaving the calcification, IVL provides a safer and less invasive alternative, particularly for elderly patients with comorbidities who are unsuitable candidates for open-heart or highly invasive interventions.

The growing pool of elderly patients underscores the importance of IVL. By 2040, the U.S. alone is projected to have 80 million people aged 65 and above, creating a significant demand base for therapies that are effective yet minimally invasive. The rise in lifestyle-related risk factors such as obesity, smoking, diabetes, and sedentary behavior further intensifies the global cardiovascular disease burden, creating fertile ground for IVL adoption.

Key Market Highlights

• Market Size (2025): US$1,036.2 Mn

• Market Size (2032): US$2,837.7 Mn

• CAGR (2025–2032): 15.5%

• Historical CAGR (2019–2024): 84.1%

Drivers of Growth

Increasing Prevalence of Vascular Calcification

Vascular calcification has emerged as a critical global health concern. It is most commonly associated with aging and chronic conditions such as diabetes, chronic kidney disease, and hypertension. Studies indicate that 30–40% of adults over 65 years of age exhibit some level of vascular calcification, significantly elevating their risk for cardiovascular events such as strokes and heart attacks.

IVL technology directly addresses this problem by safely fragmenting calcium within the arterial walls, thereby restoring vessel flexibility and enhancing treatment outcomes. For patients with severe arterial calcification, who often face limited treatment choices, IVL provides a safer alternative to more invasive techniques.

Patient Preference for Minimally Invasive Cardiovascular Treatments

Globally, patients are becoming increasingly aware of their healthcare options, leading to higher demand for minimally invasive treatments. IVL procedures deliver several advantages, including shorter recovery times, reduced complication risks, and lower post-procedural discomfort. Elderly patients and those with multiple comorbidities, who may not withstand open-heart surgery, are particularly inclined toward such options.

The rise in patient-centric healthcare, combined with advancements in device technology, ensures that IVL adoption will continue to grow steadily in both developed and emerging markets.

Technological Innovations and Clinical Advancements

Technological progress remains a central driver of IVL market expansion. Integration of imaging modalities such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allows clinicians to achieve higher procedural precision and improved patient outcomes. These imaging tools enable real-time visualization of arterial calcification, guiding catheter placement and optimizing shockwave delivery.

Furthermore, clinical trials continue to validate IVL’s safety and efficacy. In June 2024, AVS received an IDE approval from the FDA for its Pulse IVL™ pivotal trial in the U.S., aimed at treating patients with severely calcified peripheral arterial disease. Such advancements not only strengthen clinical confidence but also accelerate regulatory approvals worldwide.

Market Restraints

High Costs of IVL Devices

Despite its effectiveness, the high cost of IVL devices presents a significant barrier to widespread adoption. These advanced technologies require substantial investment in research, design, and precision manufacturing, which drives up device prices. Hospitals in developing regions, or facilities with limited budgets, often find IVL systems financially challenging to procure.

The cost challenge extends to patients, many of whom face higher out-of-pocket expenses due to limited insurance coverage. Until production costs stabilize or reimbursement frameworks expand, affordability will remain a key constraint in the market.

Opportunities

Growing Adoption in Emerging Markets

Emerging economies represent some of the most promising opportunities for IVL expansion. Countries in Asia Pacific, Latin America, and the Middle East are witnessing improvements in healthcare infrastructure, higher healthcare spending, and greater awareness of cardiovascular disease. These factors, combined with an increasing elderly population, create strong demand for minimally invasive cardiovascular treatments.

Integration of Imaging for Enhanced Precision

The continued integration of IVL with advanced imaging techniques offers a major growth avenue. Enhanced visualization ensures accurate plaque assessment and targeted therapy, minimizing complications and repeat interventions. The synergy of IVL with IVUS and OCT not only improves safety but also strengthens its competitive advantage over other revascularization methods.

Category-wise Analysis

By Product Type

The coronary intravascular lithotripsy systems segment is expected to maintain dominance, accounting for 69.3% of the market in 2025. These systems are particularly effective in treating complex coronary lesions that pose challenges for angioplasty and stent deployment.

By Disease Indication

The coronary artery disease (CAD) segment will lead with 60.4% market share in 2025, reflecting the global rise in CAD prevalence. Factors such as obesity, diabetes, smoking, and sedentary lifestyles are driving demand for advanced treatment options, and IVL is increasingly positioned as a front-line intervention for complex cases.

Regional Insights

North America

North America will continue to dominate, accounting for 79.8% of the market in 2025. The region benefits from advanced healthcare infrastructure, robust reimbursement policies, and high levels of awareness among both patients and clinicians. Strong regulatory frameworks and ongoing clinical trials further strengthen its leadership position.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region, fueled by a rapidly aging population, growing incidence of cardiovascular diseases, and expanding access to advanced medical technologies. Countries such as China and India are investing heavily in healthcare infrastructure, presenting attractive growth prospects for IVL companies.

Competitive Landscape

The IVL market is characterized by rapid innovation and intensifying competition. For nearly a decade, Shockwave Medical (Johnson & Johnson) dominated the global market. However, competition is heating up:

• In January 2025, Boston Scientific acquired Bolt Medical, whose IVL system secured FDA approval in mid-2025, creating direct competition with Shockwave.

• Abbott is also entering the field, with clinical trials for its IVL device expected to start soon.

• MicroPort received NMPA approval in China for its TomaHawk™ coronary IVL system in January 2025.

• Amplitude Vascular Systems (AVS) continues trials of its Pulse IVL system, following collaborations with the Jacobs Institute.

Emerging players are targeting underserved regions, while established giants expand their portfolios and scale manufacturing to solidify market presence.

Recent Developments

• January 2025: MicroPort® gains NMPA approval for TomaHawk™ IVL system in China.

• April 2024: Acquisition of Shockwave Medical strengthens Johnson & Johnson’s cardiovascular portfolio.

• March 2024: Fast Wave Medical enters the IVL market with innovative systems targeting calcific artery disease.

• August 2024: AVS partners with Jacobs Institute to accelerate Pulse IVL trials.

Companies Covered in the IVL Market

• Shockwave® Medical Inc. (Johnson & Johnson Services, Inc.)

• Bolt Medical, Inc. (Boston Scientific)

• Cardiovascular Systems, Inc. (Abbott)

• AVS Pulse, Inc.

• Spectrumedics International

• MicroPort Scientific

• Elixir Medical

Outlook

The global intravascular lithotripsy (IVL) market is set to experience robust growth through 2032. The technology’s ability to address heavily calcified arterial lesions in a safe, minimally invasive manner positions it as a game-changing tool in cardiovascular care. While high device costs remain a limiting factor, continued innovation, broader regulatory approvals, and growing adoption in emerging markets are expected to offset this challenge.

As more players enter the field and integrate advanced imaging technologies, the IVL market will evolve rapidly, with opportunities expanding beyond developed markets into new geographies. With a strong CAGR of 15.5% projected between 2025 and 2032, the IVL industry is poised to reshape the landscape of cardiovascular treatment worldwide.